21. FMO2 Prevents Pathological Cardiac Hypertrophy by Maintaining the ER-Mitochondria Association Through Interaction With IP3R2-Grp75-VDAC1.
作者: Changchen Xiao.;Chao Wang.;Jingyi Wang.;Xianpeng Wu.;Changle Ke.;Jinliang Nan.;Hao Ding.;Yinghui Xu.;Yanna Shi.;Jing Zhao.;Cheng Ni.;Qingnian Liu.;Jiamin Li.;Shuyuan Sheng.;Hua Chen.;Jiayue Cai.;Tonghui Zhao.;Jinghai Chen.;Qiming Sun.;Bin Zhou.;Jian'an Wang.;Wei Zhu.;Xinyang Hu.
来源: Circulation. 2025年151卷23期1667-1685页
Cardiac hypertrophy, as an important pathological change, contributes to heart failure. Recent studies indicate that the mitochondria-associated endoplasmic reticulum membranes (MAMs) play key roles in this pathological process. However, the molecular mechanism remains unclear. This study aims to elucidate the effects and mechanisms of MAM-resident FMO2 (flavin-containing monooxygenase 2) in cardiac hypertrophy and heart failure.
22. Alcohol Use and Cardiovascular Disease: A Scientific Statement From the American Heart Association.
作者: Mariann R Piano.;Gregory M Marcus.;Dawn M Aycock.;Jennifer Buckman.;Chueh-Lung Hwang.;Susanna C Larsson.;Kenneth J Mukamal.;Michael Roerecke.; .
来源: Circulation. 2025年
Alcohol is one of the most commonly consumed substances in the world, exhibiting complex relationships with multiple aspects of cardiovascular health and disease. The majority of the research on the topic is observational and therefore prone to bias and confounding. The available evidence suggests no risk to possible risk reduction when alcohol is consumed in low amounts (such as no more than 1 to 2 drinks a day) in regard to coronary artery disease, stroke, sudden death, and possibly heart failure. The risk associated with consuming 1 to 2 drinks a day on atrial fibrillation remains unknown. More randomized trials of low to moderate alcohol consumption are needed for more definitive conclusions. In stark contrast, heavier alcohol consumption such as binge drinking or consuming on average ≥3 drinks/d is consistently associated with worse outcomes in every cardiovascular disease entity studied. Considering the level of evidence, it remains unknown whether drinking is part of a healthy lifestyle and therefore clinicians should reinforce healthy lifestyle behaviors such as regularly engaging in physical activity, avoiding tobacco use, and maintaining healthy body weight.
23. A Nationwide Factorial Randomized Trial of Electronic Nudges to Patients with Chronic Kidney Disease and Their General Practices for Increasing Guideline-Directed Medical Therapy: The NUDGE-CKD Trial.
作者: Kristoffer Grundtvig Skaarup.;Niklas Dyrby Johansen.;Lisbet Brandi.;Morten Kofod Lindhardt.;Jesper N Bech.;My Svensson.;Tilde Kristensen.;Anne Daugaard Thuesen.;Majbritt Grønborg Knudsen.;Jan Dominik Kampman.;Mads Hornnum.;Birgitte Ørts.;Daniel Modin.;Mats C H Lassen.;Kira Hyldekær Janstrup.;Brian L Claggett.;Muthiah Vaduganathan.;Ankeet S Bhatt.;Harriette G C Van Spall.;Jens Ulrik Stæhr Jensen.;Faiez Zannad.;Scott D Solomon.;Anne Møller.;Rikke Borg.;Henrik Birn.;Ditte Hansen.;Tor Biering-Sørensen.
来源: Circulation. 2025年
Many individuals with chronic kidney disease (CKD) face considerable but modifiable risk of cardiovascular and renal outcomes due to suboptimal implementation of guideline-directed medical therapy (GDMT). We investigated whether electronic letter-based nudges delivered to individuals with CKD and their general practices could increase GDMT uptake.
24. High Dietary Phosphate Intake Induces Hypertension and Sympathetic Overactivation Through Central Fibroblast Growth Factor Receptor Signaling.
作者: Han-Kyul Kim.;Ayumi Fukazawa.;Scott A Smith.;Masaki Mizuno.;Beverly A Rothermel.;Teppei Fujikawa.;Marco Galvan.;Laurent Gautron.;Johanne V Pastor.;Isabelle Carroll.;Orson W Moe.;Wanpen Vongpatanasin.
来源: Circulation. 2025年
Recent studies have highlighted the deleterious role of high phosphate intake in hypertension by means of sympathetic overactivation, yet the underlying mechanisms remain unclear. Dietary phosphate loading triggers physiologic release of FGF23 (fibroblast growth factor-23) from the bone to maintain phosphate homeostasis. Both FGF23 and FGF receptors (FGFRs) are present in the central nervous system, but their role in neural control of blood pressure during phosphate loading is unknown. We investigated central FGF23/FGFR signaling in high-phosphate diet-induced sympathetic dysregulation of blood pressure in rats.
25. Burden of Cardiovascular Outcomes After SARS-CoV-2 Infection in South Korea and Japan: A Binational Population-Based Cohort Study.
作者: Sooji Lee.;Seung Ha Hwang.;Seoyoung Park.;Yejun Son.;Soeun Kim.;Hyeon Jin Kim.;Jaeyu Park.;Hyesu Jo.;Kyeongmin Lee.;Jiyeon Oh.;Min Seo Kim.;Damiano Pizzol.;Lee Smith.;Jinseok Lee.;Ho Geol Woo.;Hayeon Lee.;Dong Keon Yon.
来源: Circulation. 2025年
Despite the significant global impact of the COVID-19 pandemic, limited studies have investigated the long-term cardiovascular sequelae of SARS-CoV-2 infection, particularly among Asian populations. This large-scale, population-based binational cohort study with long-term follow-up aimed to investigate the association between SARS-CoV-2 infection and the risk of cardiovascular events.
26. Left Atrial to Left Ventricular Volume Ratio in Patients With Severe Functional Mitral Regurgitation.
作者: Sophia Koschatko.;Gregor Heitzinger.;Noemi Pavo.;Georg Spinka.;Suriya Prausmüller.;Katharina Mascherbauer.;Varius Dannenberg.;Christoph Torrefranca.;Matthias Koschutnik.;Carolina Donà.;Raphael Rosenhek.;Charlotte Jantsch.;Kseniya Halavina.;Laurenz Hauptmann.;Rayyan Hemetsberger.;Christian Nitsche.;Caglayan Demirel.;Christian Hengstenberg.;Martin Hülsmann.;Georg Goliasch.;Philipp E Bartko.
来源: Circ Cardiovasc Imaging. 2025年e017872页
Severe functional mitral regurgitation (fMR) is a heterogenous disease that exhibits different underlying pathophysiological mechanisms and represents independent entities. The aim of this study was to characterize remodeling patterns defined by the left atrial (LA) to left ventricular (LV) volume ratio in patients with severe fMR and heart failure, and to examine its prognostic implications.
27. Machine Learning to Automatically Differentiate Hypertrophic Cardiomyopathy, Cardiac Light Chain, and Cardiac Transthyretin Amyloidosis: A Multicenter CMR Study.
作者: Lukas Damian Weberling.;Andreas Ochs.;Mitchel Benovoy.;Fabian Aus dem Siepen.;Janek Salatzki.;Evangelos Giannitsis.;Chong Duan.;Kevin Maresca.;Yao Zhang.;Jan Möller.;Silke Friedrich.;Stefan Schönland.;Benjamin Meder.;Matthias G Friedrich.;Norbert Frey.;Florian André.
来源: Circ Cardiovasc Imaging. 2025年e017761页
Cardiac amyloidosis is associated with poor outcomes and is caused by the interstitial deposition of misfolded proteins, typically ATTR (transthyretin) or AL (light chains). Although specific therapies during early disease stages exist, the diagnosis is often only established at an advanced stage. Cardiovascular magnetic resonance (CMR) is the gold standard for imaging suspected myocardial disease. However, differentiating cardiac amyloidosis from hypertrophic cardiomyopathy may be challenging, and a reliable method for an image-based classification of amyloidosis subtypes is lacking. This study sought to investigate a CMR machine learning (ML) algorithm to identify and distinguish cardiac amyloidosis.
28. Aortic Aneurysm Risk and Somatic JAK2V617FVariation: Insights From a Multicenter, Population-Based Cardiovascular Screening Study.
作者: Lasse M Obel.;Joachim S Skovbo.;Axel C P Diederichsen.;Mads Thomassen.;Lasse Kjær.;Morten K Larsen.;Trine A Knudsen.;Vibe Skov.;Torben A Kruse.;Mark Burton.;Maja Dembic.;Troels Wienecke.;Maria Sabater-Lleal.;Oke Gerke.;Niels E Bruun.;Christina Ellervik.;Mette Brabrand.;Flemming H Steffensen.;Lars Frost.;Jess Lambrechtsen.;Martin Busk.;Grazina Urbonaviciene.;Kenneth Egstrup.;Marek Karon.;Søren Feddersen.;Lars M Rasmussen.;Hans C Hasselbalch.;Jes S Lindholt.
来源: Circulation. 2025年
The somatic JAK2V617F sequence variation, a key driver of myeloproliferative neoplasms, has been associated with increased risk of aortic aneurysms. This study aimed to explore associations between the JAK2V617F variant allele frequency (VAF) and ascending, descending, and abdominal aortic aneurysms.
29. Joint Exposure to Ozone and Temperature and Acute Myocardial Infarction Among Adults Aged 18 to 64 Years in the United States.
作者: Lingzhi Chu.;Rong Wang.;Cary P Gross.;Jing Wei.;Yuan Lu.;Harlan M Krumholz.;Xiaomei Ma.;Kai Chen.
来源: Circulation. 2025年
Previous research suggests that exposures to air pollution and nonoptimal temperatures are associated with a higher risk of acute myocardial infarction (AMI), but few studies examined the exposures jointly. Furthermore, moderate exposures were often overlooked. We evaluated short-term exposure to ambient ozone pollution and ambient temperature jointly and over the entire range of exposures, with the occurrence of AMI among adults aged 18 to 64 years (an understudied population) in the contiguous United States.
30. Hierarchical Composite Outcomes and Win Ratio Methods in Cardiovascular Trials: A Review and Consequent Guidance.
作者: John Gregson.;Dylan Taylor.;Ruth Owen.;Tim Collier.;David J Cohen.;Stuart Pocock.
来源: Circulation. 2025年151卷22期1606-1619页
The win ratio is a method for analyzing a hierarchical composite outcome. It has been most widely used in randomized clinical trials (RCTs) in cardiovascular disease. We performed a review of cardiovascular RCTs using the win ratio published between January 2022 and July 2024. The aims were to summarize current use and to provide examples to illustrate effective use and communication. We identified 36 eligible RCTs, mainly in heart failure and ischemic heart disease. Intervention was pharmaceutical in 26, a procedure in 7, and treatment strategy in 3 trials. When outcomes were analyzed with both conventional composite end points or hierarchical analysis, the conclusions tended to be similar. The win ratio was often used to combine evidence from event outcomes and quantitative measures together in a hierarchical composite, as was done in 23 RCTs. It was also used to create a clinically more relevant measure in RCTs by recognizing the clinical priorities among event outcomes. Selected example RCTs illustrate how the clarity of win ratio findings can be improved by (1) complementing the win ratio (a relative measure) with the win difference, (2) identifying which components of a hierarchical composite drive the overall results, and (3) clearly prespecifying the outcomes and win ratio analysis to be used. We conclude with a set of recommendations for future use of hierarchical composite outcomes and the win ratio. When used wisely, the win ratio is a valuable tool in the analysis of RCTs.
31. Impact of Initial Extensive Ablation on Left Atrial Gaps During Redo Procedures and Subsequent Outcomes in Persistent Atrial Fibrillation.
作者: Masato Okada.;Koichi Inoue.;Nobuaki Tanaka.;Masaharu Masuda.;Tetsuya Watanabe.;Nobuhiko Makino.;Yasuyuki Egami.;Takafumi Oka.;Hitoshi Minamiguchi.;Miwa Miyoshi.;Takashi Kanda.;Yasuhiro Matsuda.;Masato Kawasaki.;Koji Tanaka.;Yuko Hirao.;Shungo Hikoso.;Akihiro Sunaga.;Tomoharu Dohi.;Daisaku Nakatani.;Katsuki Okada.;Yohei Sotomi.;Yasushi Sakata.; .
来源: Circ Arrhythm Electrophysiol. 2025年18卷6期e013612页
The efficacy of extensive linear ablation strategies, in addition to pulmonary vein (PV) isolation, remains controversial in persistent atrial fibrillation (AF) ablation. Gaps in previously ablated lesions can induce arrhythmias and potentially decrease the effectiveness of extensive ablation. This study evaluated the incidence of conduction gaps, gap-related reentry, and subsequent recurrence following redo AF ablation in the EARNEST-PVI trial (Efficacy of Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation; REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03514693).
32. Pulmonary Circulation in Advanced Heart Failure and Cardiogenic Shock: State-of-the-Art Review.
作者: Sara L Hungerford.;Kay Everett.;Edmund Lau.;Daniel Burkhoff.;Navin K Kapur.
来源: Circ Heart Fail. 2025年e012611页
The pulsatile nature of blood flow and the hydrostatic effect of pulmonary capillary wedge pressure are 2 fundamental, yet often overlooked features of right ventricular-pulmonary arterial interactions in advanced heart failure and cardiogenic shock. These 2 features (above all others) define both the mechanical forces experienced by the pulmonary arteries, and in turn, the vascular afterload imposed by the pulmonary circulation on the right ventricular. For over half a century, it has been assumed that the pulsatile components of the pulmonary circulation exist in predictable and constant proportion to resistive afterload. In other words, that the vascular afterload can be estimated from mean pulmonary arterial pressure and pulmonary vascular resistance alone. While this tenet holds true for most forms of pulmonary hypertension, pulmonary hypertension resulting from the passive transmission of elevated left atrial pressure is a notable exception. In these cases, arterial compliance decreases proportionally more than any increase in pulmonary vascular resistance and is highly dependent upon recruitment and distensibility of the pulmonary circulation. As questions regarding the optimal method to predict right ventricular failure resurface, along with a modern armamentarium of techniques to assess pulsatile pressure-flow relations, it serves as a timely reminder that, in those with normal or near-normal pulmonary arterial pressures, the pulsatile component of pulmonary vascular afterload may account for anywhere between one-quarter and half of the total power of the right ventricular. In this State-of-the-Art Review, we address the role of pulmonary circulation in those with advanced heart failure and cardiogenic shock. Unlike previous discussions on this topic, we set aside considerations of established precapillary disease, focusing specifically on the process by which an acute or chronic elevation of pulmonary capillary wedge pressure results in pulmonary hypertension from left-sided heart failure. In doing so, we create a framework to assess pulmonary vascular afterload in an era of advanced therapeutics and device technologies to treat advanced heart failure and cardiogenic shock.
33. Steal Phenomenon of Thoracic False Lumen: Imaging Insights From Postdissection Cases.
Persistent thoracic false lumen flow and subsequent aortic expansion are common complications following thoracic endovascular aortic repair for type B aortic dissection, as well as aortic arch replacement with the elephant trunk technique for type A aortic dissection. Although thoracic false lumen-perfused branches are known to contribute to thoracic false lumen backflow, robust imaging evidence is still lacking. This review illustrates how these branches perpetuate thoracic false lumen flow through detailed imaging analysis, emphasizing the critical need for advancing rapid, accurate, and minimally invasive imaging techniques and novel therapeutic devices to address this persistent clinical challenge.
34. Resuscitation Practices at Emergency Medical Service Agencies Working in Black and Hispanic Versus White Catchment Areas in the United States.
作者: Paul S Chan.;Saket Girotra.;Khadijah Breathett.;Kimberly C Dukes.;Jessica Sperling.;Christina M Pacheco.;Kevin F Kennedy.;Comilla Sasson.;Bryan McNally.;Heather Schacht Reisinger.;Marina Del Rios.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷6期e011799页
Although survival for out-of-hospital cardiac arrest (OHCA) is lower at emergency medical service (EMS) agencies serving Black/Hispanic communities, it is unknown whether this is due to practice differences.
35. Validation of ICD-10 Codes to Distinguish Between Claudication and Chronic Limb-Threatening Ischemia in Patients Undergoing Peripheral Vascular Intervention Using Medicare-Matched Registry Data.
作者: Sanuja Bose.;David P Stonko.;Sharon C Kiang.;Daniel Roh.;Jialin Mao.;Andrew Cabrera.;Chen Dun.;Philip P Goodney.;James H Black.;Leigh Ann O'Banion.;Jesse A Columbo.;Roger T Tomihama.;Caitlin W Hicks.
来源: Circ Cardiovasc Qual Outcomes. 2025年e011467页
The accuracy of contemporary administrative claims codes to discriminate between different phenotypes of peripheral artery disease is not well defined. We aimed to validate a predefined set of International Classification of Diseases, Tenth Revision, codes used to distinguish between claudication and chronic limb-threatening ischemia (CLTI) and to optimize their diagnostic accuracy using a supervised machine-learning approach.
36. Left Heart Abnormalities in Patients With Lung Disease, OSA, and Chronic Thromboemboli at Risk for or With Known Pulmonary Hypertension.
作者: Yogesh N V Reddy.;Robert P Frantz.;Paul M Hassoun.;Anna Hemnes.;Evelyn Horn.;Jane A Leopold.;Franz Rischard.;Erika B Rosenzweig.;Nicholas S Hill.;Serpil C Erzurum.;Gerald J Beck.;J Emanuel Finet.;Christine L Jellis.;Stephen C Mathai.;Reena Mehra.;W H Wilson Tang.;Barry A Borlaug.; .
来源: Circ Heart Fail. 2025年e012912页
Patients with lung disease, sleep apnea, and chronic thromboemboli can develop pulmonary hypertension, currently classified as group 3 or 4. Many of these patients also have risk factors for heart failure with preserved ejection fraction (HFpEF), but the optimal approach to identify the disease overlap remains unclear.
37. Procedural and Clinical Outcomes According to Ultrasound-Guided Access in TAVI: A Propensity-Matched Comparative Subanalysis From the PULSE Registry.
作者: David Grundmann.;Tanja Rudolph.;Matti Adam.;Caroline Kellner.;Sabine Bleiziffer.;Daniel Braun.;Alexander R Tamm.;Max Meertens.;Matthias Renker.;Jonas Gmeiner.;Alexander Sedaghat.;David Leistner.;Christian W Hamm.;Hendrik Wienemann.;Norvydas Zapustas.;Benjamin Juri.;Mostafa Salem.;Roman Benetti-Lehmann.;Henryk Dreger.;Alina Gossling.;Awesta Nahif.;Stefan Blankenberg.;Hermann Reichenspurner.;Niklas Schofer.;Andreas Schaefer.;Jasmin Popara.;Misumasa Sudo.;Martin Geyer.;Marc Vorpahl.;Derk Frank.;Max Potratz.;Won Kim.;Moritz Seiffert.
来源: Circ Cardiovasc Interv. 2025年e014771页
Access-related vascular and bleeding complications during transcatheter aortic valve implantation (TAVI) are associated with significant morbidity and mortality. Ultrasound-guided (USG) puncture may reduce the incidence of these adverse events, particularly in large-bore arterial access. However, large-scale data on this approach are limited, and it has not yet been fully implemented into standard clinical practice. We compared access-related vascular and bleeding complications in USG versus fluoroscopy-guided access from a large multicenter TAVI registry.
38. Long-Term Risk Assessment in Athletes With Complex Ventricular Arrhythmias.
作者: Paolo Compagnucci.;Michela Casella.;Maria Lucia Narducci.;Edoardo Conte.;Michela Cammarano.;Gemma Pelargonio.;Daniele Andreini.;Vincenzo Palmieri.;Giulia Stronati.;Gerardo V Lo Russo.;Matteo Brusamolino.;Gianluca Pontone.;Federico Guerra.;Andrea Natale.;Claudio Tondo.;Filippo Crea.;Paolo Zeppilli.;Antonio Dello Russo.
来源: Circ Arrhythm Electrophysiol. 2025年18卷6期e013480页
Ventricular arrhythmias (VAs) are a major concern in athletes. We sought to determine the prognostic role of noninvasive and invasive assessments in athletes with complex VAs.
39. Association of Pathogenic/Likely Pathogenic Genetic Variants for Cardiomyopathies With Clinical Outcomes: A Multiancestry Analysis in the All of Us Research Program.
作者: Naman S Shetty.;Akhil Pampana.;Mokshad Gaonkar.;Nirav Patel.;Nehal Vekariya.;J Gustav Smith.;Rajat Kalra.;C Anwar A Chahal.;Christopher Semsarian.;Peng Li.;Garima Arora.;Pankaj Arora.
来源: Circ Genom Precis Med. 2025年18卷3期e005113页
This study aimed to evaluate the prevalence of pathogenic/likely pathogenic cardiomyopathy variant carriers in a multiancestry US population and examine the risk of adverse clinical outcomes.
40. Ethical Considerations for Informed Consent in Acute Myocardial Infarction Clinical Trials.
作者: Manasi Tannu.;W Schuyler Jones.;John H Alexander.;Roxana Mehran.;Adrian F Hernandez.;Jennifer A Rymer.
来源: Circ Cardiovasc Interv. 2025年e015016页
Obtaining informed consent for clinical trial participation in acute myocardial infarction presents unique ethical and logistical challenges because of the patient distress, sedation, and the urgency of treatment. Traditional consent procedures often conflict with the narrow enrollment windows, prompting the use of legally authorized representatives and short- and long-form consent models. Although these approaches enable faster trial enrollment, they may compromise patient autonomy, introduce selection bias, or create postenrollment ethical dilemmas. This review explores the complexities of informed consent in acute myocardial infarction research, evaluating the advantages and limitations of existing strategies, including legally authorized representative consent, 2-step consent processes, and alternatives such as deferred and verbal consent. It also examines international variations in regulatory oversight and presents emerging solutions, such as preemptive consent, opt-out models, electronic platforms, and registry-based trials, to streamline the enrollment without delaying care. Ultimately, consent regulations should be re-evaluated and potentially relaxed to better support timely research. A thoughtful reassessment of consent frameworks is essential to ethically and effectively advance acute myocardial infarction research in time-sensitive settings.
|